Liquidia Corporation’s stock took a significant hit after the FDA granted tentative approval to their drug YUTREPIA for treating pulmonary hypertension. The approval comes with a catch – regulatory exclusivity granted to United Therapeutics for Tyvaso DPI, which delays YUTREPIA’s full market entry until 2025. Liquidia plans to challenge this decision.
Results for: Yutrepia
US stock futures saw a slight upward trend on Monday morning, with the S&P 500 futures gaining 0.1%. However, shares of Liquidia Corporation (LQDA) plummeted in pre-market trading after the company announced the FDA’s tentative approval of YUTREPIA inhalation powder for treating pulmonary hypertension. Several other stocks also experienced losses in pre-market trading, including YXT.COM GROUP HOLDING LIMITED (YXT), Mereo BioPharma Group plc (MREO), BW LPG Limited (BWLP), Shake Shack Inc. (SHAK), Serve Robotics Inc. (SERV), Himalaya Shipping Ltd. (HSHP), and Applied Digital Corp (APLD).